7527456

Source:http://linkedlifedata.com/resource/pubmed/id/7527456

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0030705, umls-concept:C0146224, umls-concept:C0205179, umls-concept:C0280100, umls-concept:C0920321, umls-concept:C1516238, umls-concept:C2603343
pubmed:issue	12
pubmed:dateCreated	1995-1-12
pubmed:abstractText	The objectives of this phase I trial were to determine the dose-limiting toxicities (DLTs) of the novel topoisomerase I inhibitor topotecan combined with cisplatin, to define the maximum-tolerated doses (MTDs) of the combination without and with the use of filgrastim, and to define recommended doses for phase II trials.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 11789, http://linkedlifedata.com/resource/pubmed/grant/CA 26806, http://linkedlifedata.com/resource/pubmed/grant/CA 47555
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Filgrastim, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Topotecan
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0732-183X
pubmed:author	pubmed-author:FieldsS ZSZ, pubmed-author:HargisJ BJB, pubmed-author:LilenbaumR CRC, pubmed-author:MillerA AAA, pubmed-author:RosnerG LGL, pubmed-author:SchilskyR LRL
pubmed:issnType	Print
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2743-50
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:7527456-Adult, pubmed-meshheading:7527456-Aged, pubmed-meshheading:7527456-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7527456-Breast Neoplasms, pubmed-meshheading:7527456-Camptothecin, pubmed-meshheading:7527456-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:7527456-Cisplatin, pubmed-meshheading:7527456-Colorectal Neoplasms, pubmed-meshheading:7527456-Dose-Response Relationship, Drug, pubmed-meshheading:7527456-Female, pubmed-meshheading:7527456-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:7527456-Humans, pubmed-meshheading:7527456-Kidney Neoplasms, pubmed-meshheading:7527456-Lung Neoplasms, pubmed-meshheading:7527456-Male, pubmed-meshheading:7527456-Middle Aged, pubmed-meshheading:7527456-Neoplasms, pubmed-meshheading:7527456-Neoplasms, Unknown Primary, pubmed-meshheading:7527456-Neutropenia, pubmed-meshheading:7527456-Recombinant Proteins, pubmed-meshheading:7527456-Salivary Gland Neoplasms, pubmed-meshheading:7527456-Stomach Neoplasms, pubmed-meshheading:7527456-Topotecan
pubmed:year	1994
pubmed:articleTitle	Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
pubmed:affiliation	University of Tennessee, Memphis 38163.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase I